Joshua K. Sabari
Assistant professor in the Department of Medicine at the New York University Grossman School of Medicine and the director of High Reliability Organization Initiatives at the Perlmutter Cancer Center. He is an expert in the treatment of lung cancer.
Best podcasts with Joshua K. Sabari
Ranked by the Snipd community
Aug 25, 2025 • 13min
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
Dr. Joshua Sabari, a medical oncologist at NYU Langone Cancer Center, shares his expertise on the groundbreaking approval of Zongertinib for HER2-mutated non-small cell lung cancer. He discusses the prevalence of HER2 mutations, revealing key study findings with impressive response rates and progression-free survival data. The podcast dives into the management of side effects, particularly diarrhea, and compares Zongertinib with trastuzumab deruxtecan in treatment settings. Dr. Sabari also explores future directions for HER2-targeted therapies.
Jul 24, 2025 • 10min
S13 Ep35: Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD
In this discussion, Dr. Joshua K. Sabari, an expert in lung cancer at NYU Grossman School of Medicine, dives into the promising new treatment, telisotuzumab vedotin, for c-Met overexpressing NSCLC. He highlights significant results from the phase 2 LUMINOSITY study and discusses how this therapy could shift the treatment landscape. Dr. Sabari also addresses ongoing trials that may redefine patient management, emphasizing the importance of balancing efficacy with the careful monitoring of potential toxicities.
